Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ETNB

89bio Inc

Jan 29 • 03:03PM ET

8.80

Dollar change -0.21
Percentage change -2.33	%

Healthcare • Biotechnology • USA • NASD

Peers: AKRO MDGL VKTX GNFT CENTA CGEN NBIX GILD VYGR PRTA

| Held by: VTI IWM VXF XBI IWN IBB SCHA VTWO FESM VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.91	Insider Own	4.21%	Shs Outstand	117.58M	Perf Week	30.37%
Market Cap	1.03B	Forward P/E	-	EPS next Y	-2.74	Insider Trans	0.02%	Shs Float	112.63M	Perf Month	9.86%
Income	-288.96M	PEG	-	EPS next Q	-0.81	Inst Own	92.61%	Short Float	7.42%	Perf Quarter	11.82%
Sales	0.00M	P/S	-	EPS this Y	-63.25%	Inst Trans	8.17%	Short Ratio	5.15	Perf Half Y	-4.35%
Book/sh	3.56	P/B	2.47	EPS next Y	16.08%	ROA	-62.93%	Short Interest	8.35M	Perf Year	-13.47%
Cash/sh	3.60	P/C	2.44	EPS next 5Y	-11.90%	ROE	-73.31%	52W Range	5.99 - 16.63	Perf YTD	12.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.24%	ROI	-69.64%	52W High	-47.08%	Beta	1.07
Dividend TTM	-	Quick Ratio	11.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	47.02%	ATR (14)	0.83
Dividend Ex-Date	-	Current Ratio	11.65	EPS Y/Y TTM	-45.57%	Oper. Margin	-	RSI (14)	65.85	Volatility	14.43% 7.86%
Employees	70	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	31.00
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-206.05%	Payout	-	Rel Volume	3.91	Prev Close	9.01
Sales Surprise	-100.00%	EPS Surprise	-122.90%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	1.62M	Price	8.80
SMA20	20.48%	SMA50	12.20%	SMA200	5.89%	Trades		Volume	5,466,528	Change	-2.33%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Resumed	BofA Securities	Buy	$30
Jan-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$24 → $15
Oct-10-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-28-23	Initiated	UBS	Buy	$36
Jun-13-23	Initiated	Evercore ISI	Outperform	$49
May-12-22	Upgrade	Raymond James	Outperform → Strong Buy	$33 → $12
Dec-20-21	Initiated	H.C. Wainwright	Buy	$46
Oct-26-21	Resumed	Cantor Fitzgerald	Overweight	$49
Jul-29-21	Resumed	BTIG Research	Buy	$60
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$65 → $35
Apr-21-21	Initiated	Cantor Fitzgerald	Overweight	$58
Oct-19-20	Initiated	Raymond James	Strong Buy	$65
Sep-25-20	Upgrade	BofA Securities	Neutral → Buy	$37 → $43
Jul-31-20	Initiated	Piper Sandler	Overweight	$54
Jul-23-20	Initiated	BTIG Research	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$58
Dec-09-19	Initiated	SVB Leerink	Outperform
Dec-09-19	Initiated	RBC Capital Mkts	Outperform
Dec-09-19	Initiated	Oppenheimer	Outperform
Dec-09-19	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Jan-28-25 10:31PM	89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:59PM	Why 89bio Stock Lagged the Market Today (Motley Fool)
Jan-27-25 04:24PM	Akero Therapeutics Stock Nearly Doubles Pulling 89bio Higher On Positive MASH Study (Investor's Business Daily) +26.23%
04:12PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-13-25 08:00AM	89bio Provides Business Update and Outlook for 2025 (GlobeNewswire)
04:05PM	Loading…
Dec-19-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.62% +12.94%
Dec-04-24 01:02PM	Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-29-24 01:30PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 04:05PM	89bio to Participate in the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-15-24 08:05AM	89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 (GlobeNewswire) -9.37%
Nov-12-24 11:58PM	89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.95%
04:01PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Nov-07-24 04:05PM	89bio Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Nov-05-24 04:05PM	89bio to Participate in the UBS Global Healthcare Conference (GlobeNewswire) +10.18%
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
04:08PM	Loading…
Nov-01-24 04:08PM	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH (Investor's Business Daily) +17.48%
Oct-18-24 01:01AM	Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings (GuruFocus.com)
Oct-17-24 01:05PM	State Street Corp's Strategic Acquisition in 89bio Inc (GuruFocus.com)
Oct-15-24 08:30AM	89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting 2024 (GlobeNewswire)
Oct-11-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-24 04:05PM	89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference (GlobeNewswire)
Sep-19-24 04:03PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-24 04:05PM	89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer (GlobeNewswire)
Sep-04-24 04:15PM	NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth (GlobeNewswire)
Aug-29-24 08:00AM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-24 08:00AM	89bio Appoints Francis Sarena as Chief Operating Officer (GlobeNewswire)
Aug-05-24 09:55PM	ETNB Stock Earnings: 89bio Beats EPS for Q2 2024 (InvestorPlace) -5.84% -5.36%
04:05PM	89bio Reports Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
08:00AM	89bio Appoints Charles McWherter, Ph.D., to its Board of Directors (GlobeNewswire)
04:05PM	Loading…
Jul-12-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
May-22-24 04:05PM	89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress (GlobeNewswire) -8.40%
May-14-24 08:00AM	89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis (GlobeNewswire)
May-10-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:16PM	89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials (GuruFocus.com)
May-09-24 10:54PM	ETNB Stock Earnings: 89bio Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 11:56PM	Jump on the Bandwagon, Says Bank of America About These 2 Stock Picks (TipRanks)
04:05PM	89bio to Participate in the BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-06-24 12:00PM	All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy (Zacks)
May-02-24 04:05PM	89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH (GlobeNewswire)
Apr-17-24 04:05PM	89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors (GlobeNewswire)
Apr-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-03-24 07:01PM	89bio Inc CEO Rohan Palekar Sells 52,718 Shares (GuruFocus.com)
Mar-27-24 08:00AM	89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal) -6.80%
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 08:00AM	89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis (GlobeNewswire)
Mar-08-24 04:05PM	89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-07-24 01:34PM	Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Crispin Odey, Glen Kacher, Julian Robertson, Nelson Peltz, Brevan Howard Asset Management, SLR Investment Corp. (SLRC), 89bio, Inc. (ETNB), and More (Insider Monkey) +7.34%
Mar-05-24 04:05PM	89bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire) -14.81%
09:55AM	Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade (Zacks)
09:30AM	89BIO (ETNB) Just Overtook the 200-Day Moving Average (Zacks)
Mar-04-24 04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily) +9.11%
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
Mar-02-24 04:31AM	89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ... (GuruFocus.com)
Feb-29-24 04:05PM	89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) +10.03%
Feb-22-24 03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-06-24 04:05PM	89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -17.04%
Feb-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 09:35AM	89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Jan-10-24 09:55AM	Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect? (Zacks)
Dec-19-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.71%
Dec-12-23 07:30AM	89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-07-23 07:00AM	89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-06-23 04:36PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-04-23 07:00AM	89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 (GlobeNewswire) +7.74%
Nov-27-23 08:00AM	89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)
Nov-21-23 04:01PM	89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference (GlobeNewswire)
Nov-12-23 12:15PM	89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 07:28AM	89bio Inc (ETNB) Reports Increased R&D and G&A Expenses in Q3 2023 (GuruFocus.com)
Nov-08-23 04:01PM	89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.27%
Oct-17-23 08:00AM	89bio to Participate in the H.C. Wainwright 7 Annual NASH Investor Conference (GlobeNewswire)
Oct-11-23 03:49AM	Texas Instruments margins in for a squeeze; Silk Road walloped: 5 big analyst cuts (Investing.com) -13.04%
Oct-10-23 04:13PM	Why Shares of 89bio Plummeted on Tuesday (Motley Fool) -37.06%
Oct-03-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-21-23 08:00AM	89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)
Sep-20-23 08:00AM	89bio to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -9.84%
Sep-05-23 08:00AM	89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 04:01PM	89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-12-23 04:30PM	89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-07-23 09:40AM	Are Medical Stocks Lagging 89BIO (ETNB) This Year? (Zacks)
08:00AM	Obesity Drugs Wont Starve These Other Potential Blockbusters (The Wall Street Journal)
Jun-24-23 05:05AM	89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine (GlobeNewswire)
05:01AM	Data from 89bios ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress (GlobeNewswire)
Jun-07-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023 (GlobeNewswire)
May-29-23 09:35AM	89BIO (ETNB) Just Overtook the 20-Day Moving Average (Zacks)
May-23-23 08:00AM	89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) (GlobeNewswire)
May-13-23 08:53AM	Institutional investors are 89bio, Inc.'s (NASDAQ:ETNB) biggest bettors and were rewarded after last week's US$90m market cap gain (Simply Wall St.)
May-05-23 09:55AM	Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know (Zacks)
May-04-23 04:05PM	89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 08:00AM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-29-23 08:25AM	3 Biotech Buyout Targets to Watch (Motley Fool)
Apr-13-23 09:55AM	Wall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High? (Zacks) +6.78%
09:40AM	Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-02-23 08:27AM	Independent Director Michael Hayden Just Bought 41% More Shares In 89bio, Inc. (NASDAQ:ETNB) (Simply Wall St.)
Mar-24-23 10:57AM	Why Shares of 89bio Soared This Week (Motley Fool)

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McWherter Charles	Director	Jan 22 '25	Buy	6.71	10,000	67,100	25,000	Jan 23 07:38 PM
McWherter Charles	Director	Jan 21 '25	Buy	6.55	5,000	32,750	15,000	Jan 23 07:38 PM
Le-Nguyen Quoc	See Remarks	Jan 15 '25	Sale	6.49	10,963	71,150	271,833	Jan 17 04:01 PM
QUOC LE-NGUYEN	Officer	Jan 15 '25	Proposed Sale	6.49	10,963	71,110		Jan 15 04:13 PM
PALEKAR ROHAN	Chief Executive Officer	Dec 06 '24	Buy	7.89	5,000	39,450	471,236	Dec 10 06:02 AM
McWherter Charles	Director	Dec 05 '24	Buy	8.00	10,000	80,000	10,000	Dec 09 06:01 AM
PALEKAR ROHAN	Chief Executive Officer	Nov 22 '24	Buy	8.35	10,000	83,500	466,236	Nov 25 06:05 AM
Le-Nguyen Quoc	See Remarks	Oct 30 '24	Sale	8.12	27,955	226,995	187,796	Nov 01 04:01 PM
QUOC LE-NGUYEN	Officer	Oct 30 '24	Proposed Sale	8.12	27,955	226,972		Oct 30 04:20 PM
PALEKAR ROHAN	Chief Executive Officer	Apr 01 '24	Option Exercise	1.93	25,000	48,250	511,889	Apr 03 04:01 PM
PALEKAR ROHAN	Chief Executive Officer	Apr 01 '24	Sale	10.91	52,718	575,153	459,171	Apr 03 04:01 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 04 '24	Buy	15.35	1,350,000	20,722,500	12,431,584	Mar 06 05:40 PM
PALEKAR ROHAN	Chief Executive Officer	Feb 26 '24	Sale	10.76	4,477	48,173	486,889	Feb 28 06:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ETNB

89bio Inc

Upgrade your FINVIZ experience